Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1 placebo-controlled safety and PK study of SAD and MAD doses of ORP-101 in healthy subjects

Next Previous
X
Search
Trial Profile

A phase 1 placebo-controlled safety and PK study of SAD and MAD doses of ORP-101 in healthy subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 09 Jul 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ORP 101 (Primary)
  • Indications Irritable bowel syndrome
  • Focus Adverse reactions
  • Sponsors OrphoMed

    • Most Recent Events

    • 19 Feb 2020 According to OrphoMed media release, Dr. Lembo, who is the Chair of OrphoMeds Scientific Advisory Board will lead clinical investigation of ORP-101 in IBS-D patients
    • 19 Feb 2020 According to OrphoMed media release, the company has announced presentation of data from this trial at Digestive Disease Week on Monday, May 4, 12:30 to 1:30 p.m. CST, at Chicagos McCormick Place Convention Center, South Hall A, Level 3.
    • 05 Jan 2018 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top